Pharmaceuticals. MN is employed by Diabeteszentrum Bad Lauterberg, Germany; has received research grants to his institution from Berlin-Chemie AG (Menarini Group), Eli Lilly and Company, Merck, Sharp & Dohme, Novartis Pharma AG, AstraZeneca, Boehringer Ingelheim, GlaxoSmithKline, MetaCure, Roche Pharma AG, Novo Nordisk Pharma GmbH, and Tolerx; has received consulting fees or honoraria for membership in advisory boards and honoraria for speaking from Amylin Pharmaceuticals LLC, AstraZeneca, Berlin-Chemie AG (Menarini group), Boehringer Ingelheim, Bristol-Myers Squibb EMEA, Diartis Pharmaceuticals, Eli Lilly and Company, F Hoﬀ  mann-LaRoche,  GlaxoSmithKline, Intarcia Therapeutics, MannKind Corp, Merck Sharp & Dohme GmbH, Novartis Pharma AG, NovoNordisk A/S, Sanoﬁ  -Aventis Pharma, Takeda, Versartis, and Wyeth Research, including